Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
42 results about "Growth factor receptor inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Growth factor receptor inhibitors (growth factor inhibitors, growth factor receptor blockers, growth factor blockers, growth factor receptor antagonists, growth factor antagonists) are drugs that target the growth factor receptors of cells. They interfere with binding of the growth factor to the corresponding growth factor receptors, impeding cell growth and are used medically to treat cancer.
EGFR inhibitor and preparing method and application thereof
InactiveCN105001208AStrong inhibitory activityGood inhibitory effectOrganic active ingredientsOrganic chemistryDiseaseProtein-Tyrosine Kinases
The invention discloses an EGFR inhibitor. The EGFR inhibitor is of the structure shown in the formula (I) and is a compound including alpha, beta-unsaturated carboxylic acid amides. Meanwhile, the invention discloses a preparing method of the compound and the application of the compound serving as a protein tyrosine kinase inhibitor, especially the inhibiting function on T790M variant EGFR as the EGFR inhibitor, and the application on treating diseases such as the kidney cancer, the ling cancer, the prostate cancer, the pancreatic cancer the breast cancer and the spongiocytoma which are related to EGFR over expression. The structure is shown in the specification.
Owner:NANJING LEIKEXING BIOTECH CO LTD
Dioxanoquinazoline amine compound and preparation method thereof, and application of dioxanoquinazoline amine compound as epidermal growth factor receptor inhibitor
ActiveCN105837586AReduce adverse effectsOrganic active ingredientsOrganic chemistryHalogenAlkoxy group
The invention discloses 3-methoxymethyl-2,3-dihydro-[1,4]dioxano[2,3-f]quinazoline-10-amine compound and a preparation method thereof, and application of the compound as an epidermal growth factor receptor inhibitor for treating cancers, belonging to the field of biology. The compound is an N-substituted phenyl-5-substituted alkoxy-3-methoxymethyl-2,3-dihydro-[1,4]dioxano[2,3-f]quinazoline-10-amine compound as shown in a formula (I) which is described in the specification, or a pharmaceutically acceptable salt or a prodrug molecule thereof. In the formula (I), R<1> is selected from a group consisting of -H, C1-5 straight-chain or branched-chain alkyl groups, alkyloxy groups, alkyloxy-substituted C1-5 straight-chain or branched-chain alkyl groups, etc.; R<2> is selected from a group consisting of -H, halogen, aromatic alkyloxy groups, C1-3 alkyl groups, and C1-3 straight-chain or branched-chain alkoxy groups; and R<3> is selected from a group consisting of -H, halogen, C1-4 unsaturated alkyl groups, nitro groups, cyano groups and C1-3 straight-chain or branched-chain alkoxy groups. The compound provided by the invention can be applied to treatment or prevention a variety of cancers.
Owner:BEIJING SCITECH MQ PHARMA LTD
Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
The present invention includes compositions and methods for the treatment and prevention of conditions associated with Human Cytomegalovirus (HCMV) infection. HCMV-associated conditions include infections (active and latent), benign cell-proliferative conditions, pre-cancerous cell-proliferative conditions, and cancerous conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3′-diindolylmethane (DIM), or a DIM-related indole, in combination with an inhibitor of a membrane bound Growth Factor Receptor (GFR), to treat conditions associated with exposure to HCMV. In certain embodiments, the compositions of the invention can be used in combination with radiation therapy.
Owner:BIORESPONSE
Anti-cancer pharmaceutical compositions and methods for treating patients with cancer
InactiveUS8263631B2BiocideOrganic chemistryProstate cancerVascular Endothelial Growth Factor Receptor
Method of treating persons having carcinoma, sarcoma or hematopoietic cancer by administering (i) a compound of the formula (I)and (ii) an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and pharmaceutical compositions for use in said method. A method for treating gastric cancer, colon cancer, lung cancer, breast cancer, pancreas cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma and leukemia by administering a compound of the formula (I).
Owner:DAIICHI SANKYO CO LTD
LED Treatment of Dermatologic Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
InactiveUS20110196353A1Treating preventing toxicityAvoid managementSurgical instrument detailsLight therapyHuman epidermal growth factor receptorLight-emitting diode
The present invention relates generally to methods of preventing or treating toxicities of the skin, hair, and / or nails, which are associated with administration of one or more epidermal growth factor receptor inhibitors, with light-emitting diode photomodulation treatment, either alone or in combination with other agents.
Owner:DELAND MAITLAND M +1
Methods and compositions for the treatment of graft failure
InactiveUS20050261283A1Reduce inhibitionReduce productionBiocideOrganic chemistryPlateletTunica intima
The present invention provides methods and compositions for treating graft failure resulting from neointimal hyperplasia. These methods and compositions feature the use of platelet derived growth factor receptor (PDGFR) inhibitor compounds, such as N-phenyl-2-pyrimidine compounds (e.g., imatinib mesylate) to inhibit the biological activity of the PDGFR.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Novel epidermal growth factor receptor inhibitor and application thereof
InactiveCN105985323AReduce diarrheaLittle side effectsOrganic chemistryAntineoplastic agentsGrowth factor receptor inhibitorEndocrinology
The invention provides a novel epidermal growth factor receptor inhibitor and an application thereof. The novel epidermal growth factor receptor inhibitor can be used as a T790M variation induced drug-resistant inhibitor.
Owner:ZHEJIANG WENDA PHARMA TECH LTD
Effects and application of artemisinin and its derivative in inhibition of platelet-derived growth factor receptor A
ActiveCN103251585AInhibition of activationArrest protein stabilityDigestive systemUrinary disorderSignalling pathwaysCell membrane
The invention relates to effects and application of artemisinin and its derivative in inhibition of platelet-derived growth factor receptor A. Particularly, artemisinin and its derivative directly act on a molecular target platelet-derived growth factor receptor A (PDGFR alpha) of a tumor and combines with PDGFR alpha on a cell membrane to inhibit activation of tyrosine kinase at the intracellular domain of PDGFR alpha, inhibit protein stability of PDGFR alpha, and promote a ubiquitin-dependent proteasome mediated degradation process. The artemisinin and its derivative has dose-dependent cell growth inhibition and migration invasion inhibition effects on PDGFR alpha highly expressed tumor cells, and also can inhibit activation of signaling pathways PI3K / AKT and MAPK / ERK.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Kit for forecasting treatment effect of epidermal growth factor receptor inhibitor
InactiveCN101586153ANo pollution involvedSuitable for useMicrobiological testing/measurementDNA/RNA fragmentationTreatment effectCuticle
The invention relates to a kit for forecasting the treatment effect of an epidermal growth factor receptor inhibitor, in particular to a specific primer and a probe for detecting the polymorphism of a nineteenth exon of an epidermal growth factor receptor gene by a PCR method, application of the same in preparing a reagent for detecting the polymorphism of the nineteenth exon of the epidermal growth factor receptor gene through a PCR amplified biological nucleic acid sample, a kit for detecting the polymorphism of the nineteenth exon of the epidermal growth factor receptor gene and application of the kit, and belongs to the field of medicaments.
Owner:BEIJING HUAANFO BIOMEDICAL RES CENT +1
Kit for forecasting treatment effect of epidermal growth factor receptor inhibitor
InactiveCN101586151AEasy to operateNo pollution involvedMicrobiological testing/measurementDNA/RNA fragmentationCuticleFactor ii
The invention relates to a specific primer and a probe for detecting the polymorphism of a twenty-first exon L861Q of an epidermal growth factor receptor gene by a PCR method, application of the same in preparing a reagent for detecting the polymorphism of the twenty-first exon L861Q of the epidermal growth factor receptor gene through a PCR amplified biological nucleic acid sample, a kit for detecting the polymorphism of the twenty-first exon L861Q of the epidermal growth factor receptor gene and application of the kit, and belongs to the field of medicine.
Owner:BEIJING HUAANFO BIOMEDICAL RES CENT +1
Bifidobacterium bifidum NX-7 and application of NX-7 in preparation of medicine for treating ischemic diseases
ActiveCN112391321APromote growthPromotes damage repairBacteriaMicroorganism based processesDiseaseVascular endothelium
The invention discloses bifidobacterium bifidum NX-7 and application of NX-7 in preparation of a medicine for treating ischemic diseases, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium bifidum NX-7 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 20115. The inactivated and non-inactivated fermentation supernatant and bacterial suspension of the bifidobacterium bifidum NX-7 can significantly promote the growth of the zebra fish subintestinal veins in vivo, significantly repair the injury of the zebra fish subintestinal veins induced by a vascular endothelial cell growth factor receptor inhibitor (PTK787), significantly promote the repair of the injury of the zebra fish tail fin, has the potential of promoting microcirculation regeneration and reconstruction, and shows the effect of being applied to in-vivo treatment of ischemic diseases. The bifidobacterium bifidum NX-7 disclosed by the invention has a huge potential application prospect in the aspect of treating ischemic diseases.
Owner:FOSHAN LANGSEE BIOTECHNOLOGY CO LTD +2
Kit for forecasting treatment effect of epidermal growth factor receptor inhibitor
InactiveCN101586152AEasy to operateAvoid blindnessMicrobiological testing/measurementDNA/RNA fragmentationCuticleFactor ii
The invention relates to a specific primer and a probe for detecting the polymorphism of a twenty-first exon L858R of an epidermal growth factor receptor gene by a PCR method, application of the same in preparing a reagent for detecting the polymorphism of the twenty-first exon L858R of the epidermal growth factor receptor gene through a PCR amplified biological nucleic acid sample, a kit for detecting the polymorphism of the twenty-first exon L858R of the epidermal growth factor receptor gene and application of the kit, and belongs to the field of medicine.
Owner:BEIJING HUAANFO BIOMEDICAL RES CENT +1
Methods And Compositions For The Treatment Of Graft Failure
InactiveUS20090041778A1Inhibit biological activityBiocideImmunoglobulins against growth factorsPlateletTunica intima
The present invention provides methods and compositions for treating graft failure resulting from neointimal hyperplasia. These methods and compositions feature the use of platelet derived growth factor receptor (PDGFR) inhibitor compounds, such as N-phenyl-2-pyrimidine compounds (e.g., imatinib mesylate), or mTOR inhibitors (e.g., rapamycin).
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Application of rhinoceros horn and rehmannia glutinosa composition in preparation of medicine for preventing and treating related rash caused by epidermal growth factor receptor inhibitor
InactiveCN105381070AGood curative effectLow toxicityDispersion deliveryUnknown materialsHepatic comaRhinoceros
The invention provides application of a rhinoceros horn and rehmannia glutinosa composition in preparation of a medicine for preventing and treating related rash caused by an epidermal growth factor receptor inhibitor. The rhinoceros horn and rehmannia glutinosa composition includes rhinoceros horns, radix paeoniae rubra, radix rehmanniae and cortex moutan serving as effective ingredients. The medicine composition prepared by rhinoceros horn and rehmannia glutinosa decoction for treating severe hepatitis, hepatic coma, uremia, allergic purpura, acute leukemia, sepsis syndrome and other symptoms is creatively used for preventing and treating the rash caused by the epidermal growth factor receptor inhibitor, is better in clinical curative effect and low in toxicity and can be taken for a long time.
Owner:ZHEJIANG UNIV
Application of insulin growth factor acceptor inhibitor PQ401 in as medicine for treating echinococcosis granulosa
The invention relates to the technical filed of an insulin growth factor acceptor inhibitor PQ401, and concretely relates to an application of the insulin growth factor acceptor inhibitor PQ401 as a medicine for treating echinococcosis granulosa. The insulin growth factor acceptor inhibitor PQ401 is a novel echinococcosis resistance medicine; in vivo and in vitro pharmacodynamic experiment data show that the PQ401 is an efficient echinococcosis resistance medicine molecule, can destroy the tissue structure of the Echinococcus granulosus vesicles and causes necrosis of a large amount of cells of the Echinococcus granulosus vesicles; in vivo pharmacodynamic experiment data show that the medicine has same echinococcosis granulose treatmetn effect with clinically commonly used albendazole; and the long term administration of albendazole by clinic echinococcosis granulosa patients causes medicine resistance, so the medicine can substitute albendazole to be used in the treatment of the echinococcosis granulosa.
Owner:THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
Application of p-hydroxyphenylacetic acid in prevention and/or treatment of cardiovascular diseases
ActiveCN111743885APromote generationIncrease the number of spawnsOrganic active ingredientsCardiovascular disorderVascular endotheliumPhenylacetic acid
The invention relates to an application of p-hydroxyphenylacetic acid in prevention and / or treatment of cardiovascular diseases. The invention finds for the first time that p-hydroxyphenylacetic acidhas a good treatment effect on vascular and cardiac injuries. For zebra fish interbody vascular (ISV) injury and subintestinal vein (SIV) growth conditions induced by a vascular endothelial cell growth factor receptor inhibitor (PTK787), p-hydroxyphenylacetic acid has a remarkable effect of promoting angiogenesis, and the generation number and the length of blood vessels can be obviously increased. The traditional Chinese medicine composition has a remarkable heart protection effect on heart failure of zebra fish induced by verapamil, arrhythmia induced by terfenadine and p-hydroxyphenylaceticacid, and can obviously reduce cardiac dilatation, relieve venous congestion and promote the heart rate to tend to be normal.
Owner:BIOLOGY INST OF SHANDONG ACAD OF SCI
Methods of treating hyperproliferative cell disorders
Disclosed are methods of treating subjects suffering from hyperproliferative cell disorders which consist of administering to those subjects a combination treatment of a specific retinoid and optionally a growth factor receptor inhibitor.
Owner:RUBIN CHARLES
Kit for forecasting treatment effect of epidermal growth factor receptor inhibitor
InactiveCN101586154AEasy to operateNo pollution involvedMicrobiological testing/measurementDNA/RNA fragmentationCuticleFactor ii
The invention relates to a kit for forecasting the treatment effect of an epidermal growth factor receptor inhibitor, in particular to a specific primer and a probe for detecting the G719S polymorphism locus of an eighteenth exon of an epidermal growth factor receptor gene by a PCR method, application of the same in preparing a reagent for detecting the G719S polymorphism locus of the eighteenth exon of the epidermal growth factor receptor gene through a PCR amplified biological sample, a kit for detecting the G719S polymorphism of the eighteenth exon of the epidermal growth factor receptor gene and application of the kit, and belongs to the field of medicaments.
Owner:BEIJING HUAANFO BIOMEDICAL RES CENT +1
Cyclic adenosine monophosphate boric acid complex, preparation method thereof, anti-tumor drug and neutron capture therapy boron agent
InactiveCN107163097AHigh selectivityHigh killing efficiencyOrganic active ingredientsSugar derivativesCancer cellNeutron capture
The invention discloses a cyclic adenosine monophosphate boric acid complex, a preparation method thereof, an anti-tumor drug and a neutron capture therapy boron agent. The cyclic adenosine monophosphate boric acid complex serves as a boron-containing compound, a boron-containing epidermal growth factor receptor inhibitor and a boron-containing nucleoside epidermal growth factor receptor inhibitor, cancer cells absorb the boron agent, propagation of the cancer cells needs a lot of nucleosides, so that the drug is enriched to sensitive targets such as cancer cell membranes, cancer cells are killed by the aid of neutron capture specificity, drug selectivity is widened, so that the killed efficiency of the cancer cells is greatly improved, and the cyclic adenosine monophosphate boric acid complex solves the problems that most boron agents in current neutron capture therapy only have single function, only the one-sided effect of selectively absorbing neutron energy to kill tumors is improved in neutron capture therapy, the killed efficiency of the cancer cells is low, and selectivity is poor.
Owner:童永彭
Application of buffalo horn rehmannia root medicinal composition in preparing medicament for preventing and treating related rash caused by epidermal growth factor receptor inhibitor
InactiveCN110179885AGood regeneration performanceImprove skin lesionsUnknown materialsDermatological disorderDiseaseSerum rash
The invention provides application of a buffalo horn rehmannia root medicinal composition in preparing a medicament for preventing and treating related rash caused by an epidermal growth factor receptor inhibitor. The buffalo horn rehmannia root medicinal composition comprises buffalo horn, peony roots, rehmannia roots and tree peony root bark as effective components. The invention creatively usesthe medicinal composition of the buffalo horn rehmannia root decoction used for severe hepatitis, hepatic coma, uremia, allergic purpura acute leukemia, septicemia and other diseases to prevent and treat the rash caused by the epidermal growth factor receptor inhibitor. The composition has good clinical curative effect and low toxicity, and can be taken for a long time.
Owner:赵琼
A method for predicting responsiveness to a treatment with an EGFR inhibitor
The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level of at least one target gene of hsa-miR-31 -3p (SEQ ID NO:1 ) miRNA in a sample of said patient, wherein said target gene of hsa-miR-31 -3p is selected from DBNDD2 and EPB41 L4B. The invention also relates to kits for measuring the expression of DBNDD2 and / or EPB41 L4B and at least one other parameter positively or negatively correlated to response to EGFR inhibitors. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.
Owner:INTEGRAGEN
Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
InactiveUS8501740B2Preventing, reducing and/or reversing opioid toleranceCombination therapy can be facilitatedOrganic active ingredientsBiocidePhysical dependenceMedicine
Methods of preventing the development and reversing or partially reversing opioid tolerance in a subject are provided herein. Such methods include the step of administering to a subject in need thereof a therapeutically effective amount of a PDGFR modulator or EGFR modulator alone or together with an opiate analgesic. The methods can also be used for the treatment of refractory neuropathic pain, physical dependence or addiction.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
EGFR (epidermal growth factor receptor) inhibitor for treating cancer and synthesis method of EGFR inhibitor
InactiveCN108610343ACheap and easy to buyEasy to operateOrganic chemistryAntineoplastic agentsSynthesis methodsPyridine
The invention discloses an EGFR (epidermal growth factor receptor) inhibitor N-(5-(1-cyclopropyl-6-((3-fluorobenzyl)amino)-2-oxo-1,4-dihydropteridin-3(2H)-yl)pyridin-3-yl)acrylamide for treating cancer and a synthesis process of the EGFR inhibitor. The synthesis condition and method are simple to operate, raw materials are cheap and easy to buy, the EGFR N-(5-(1-cyclopropyl-6-((3-fluorobenzyl)amino)-2-oxo-1,4-dihydropteridin-3(2H)-yl)pyridin-3-yl)acrylamide can be prepared on a large scale, and sufficient N-(5-(1-cyclopropyl-6-((3-fluorobenzyl)amino)-2-oxo-1,4-dihydropteridine-3(2H)-yl)pyridine-3-yl)acrylamide can be provided for the following pharmacological tests.
Owner:杨文思
Method for treating gefitinib resistant cancer
Owner:THE GENERAL HOSPITAL CORP +1
Application of insulin-like growth factor 1 receptor inhibitor BMS536924 in preparation of medicine for treating cystic hydatid disease
InactiveCN113398134AInhibitory activityLower survival rateOrganic active ingredientsAntiparasitic agentsMetaboliteReceptor
The invention relates to the technical field of medicines for treating the hydatid disease, and particularly relates to application of an insulin-like growth factor 1 receptor inhibitor BMS536924 in preparation of a medicine for treating the cystic hydatid disease. The invention discloses the application of the BMS536924 in preparation of the medicine for treating the cystic hydatid disease for the first time. In-vivo and in-vitro experimental data shows that the BMS536924 is an efficient medicine molecule for resisting to the hydatid disease; the insulin-like growth factor 1 receptor inhibitor BMS536924 has remarkable treatment effects on the cystic hydatid disease, and the treatment effects are superior to those of an albendazole metabolite, i.e., albendazole sulfoxide; the medicine effect of the BMS536924 and ABZSO combined use is better than those of single administration of the BMS536924 and the ABZSO; and meanwhile, compared with the dosage of the single albendazole sulfoxide, the dosage of the BMS536924 combined albendazole is reduced by 1 / 4 to 1 / 2, so that the dosage and the drug resistance are greatly reduced, and a very good treatment effect is achieved.
Owner:THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
Compound containing conjugated allenamide structure, preparation method, pharmaceutical composition and use thereof
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Cyclic adenosine monophosphate boronic acid complex and preparation method thereof, as well as antitumor drug and boron agent for neutron capture therapy
InactiveCN107163097BHigh selectivityHigh killing efficiencyOrganic active ingredientsSugar derivativesCancer cellAdenosine
Owner:童永彭
Composition for preventing or treating cancer, containing manassantin a and immune checkpoint inhibitor or epithelial growth factor receptor inhibitor
PendingUS20220117928A1Inhibit expressionGood effectOrganic active ingredientsAntibody ingredientsOncologyBULK ACTIVE INGREDIENT
Provided is a method for preventing and / or treating cancer, the method including administering to a subject a composition containing manassantin and an immune checkpoint inhibitor, or manassantin A and an epithelial growth factor receptor inhibitor, as active ingredients. The composition of the presently claimed subject matter is expected to be effectively used to suppress, through co-administration, the proliferation, metastasis, relapse, or resistance to anticancer therapy of various solid cancers.
Owner:KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND
Therapeutic combination comprising a Cdc7 inhibitor and an anti-neoplastic agent
ActiveUS9119877B2Less side effectsStrong synergyHeavy metal active ingredientsBiocideCell Surface ProteinsTopoisomerase-II Inhibitor
The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of an alkylating or alkylating-like agent, an antimetabolite agent, a topoisomerase I inhibitor, a topoisomerase II inhibitor, an inhibitor of a growth factor or of a growth factor receptor, an antimitotic agent, a proteasome inhibitor, an inhibitor of an anti-apoptotic protein and an antibody directed against a cell surface protein, wherein the active ingredients are present in each case in lice form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.
Owner:NERVIANO MEDICAL SERVICES SRL
Application of p-hydroxyphenylacetic acid in prevention and/or treatment of cardiovascular diseases
ActiveCN111743885BPromote generationIncrease the number of spawnsOrganic active ingredientsCardiovascular disorderVascular endotheliumPhenylacetic acid
The invention relates to the application of p-hydroxyphenylacetic acid in the prevention and / or treatment of cardiovascular diseases. The invention firstly finds that p-hydroxyphenylacetic acid has a better therapeutic effect on blood vessel and heart damage. For zebrafish interbody vessel (ISV) injury and inferior intestinal vein (SIV) growth induced by vascular endothelial cell growth factor receptor inhibitor (PTK787), p-hydroxyphenylacetic acid can significantly promote angiogenesis. increase in the number and length of blood vessels. For verapamil-induced zebrafish heart failure and terfenadine-induced arrhythmia, p-hydroxyphenylacetic acid has a significant protective effect on the heart, can significantly reduce cardiac dilation, relieve venous congestion and promote heart rate to normalize.
Owner:BIOLOGY INST OF SHANDONG ACAD OF SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com